Compare SACH & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | XLO |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | SACH | XLO |
|---|---|---|
| Price | $0.80 | $8.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 133.3K | 41.7K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.80 | $0.46 |
| 52 Week High | $1.45 | $9.89 |
| Indicator | SACH | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 26.77 | 43.22 |
| Support Level | N/A | $7.47 |
| Resistance Level | $1.12 | $8.80 |
| Average True Range (ATR) | 0.03 | 0.35 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 1.87 | 15.49 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.